<DOC>
	<DOC>NCT02973724</DOC>
	<brief_summary>The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.</brief_summary>
	<brief_title>EC95 of Remifentanil for Preventing Cough</brief_title>
	<detailed_description>At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). Extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.</detailed_description>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>ASA III patients undergoing general anesthesia for laryngomicrosurgery Anticipated difficult airway COPD, Asthma Recent URI (&lt; 2 weeks) Severe cardiac, hepatic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Extubation</keyword>
	<keyword>Remifentanil</keyword>
	<keyword>Laryngomicrosurgery</keyword>
</DOC>